<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Sturge-Weber syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Sturge-Weber syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Sturge-Weber syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marc C Patterson, MD, FRACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Moise L Levy, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Glenn A Tung, MD, FACR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 09, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sturge-Weber syndrome (SWS) is a rare congenital vascular disorder characterized by facial capillary malformation (port wine stain) and associated capillary-venous malformations affecting the brain and eye. It is
         <strong>
          not
         </strong>
         a heritable disorder. Thus, recurrence is unlikely.
        </p>
        <p class="headingAnchor" id="H6961417">
         <span class="h1">
          GENETICS AND PATHOGENESIS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           GNAQ
          </em>
         </strong>
         <strong>
          pathogenic variants
         </strong>
         – The main cause of SWS is somatic mosaic
         <em>
          GNAQ
         </em>
         pathogenic variants, as identified in a study that performed whole-genome sequencing of affected and normal tissue samples from three patients with SWS [
         <a href="#rid1">
          1
         </a>
         ]. This process identified a
         <em>
          GNAQ
         </em>
         single-nucleotide variant (c.548G→A, p.Arg183Gln) shared by affected tissue from all three patients. The variant was also found in samples of affected tissue from 23 of 26 study participants (88 percent) with SWS and 12 of 13 participants (92 percent) with nonsyndromic (isolated) port wine stains, but in none of four participants with other cerebrovascular malformations and in none of six controls. The prevalence of the variant in affected tissues ranged from 1 to 18 percent. These findings confirm the longstanding hypothesis that the capillary-venous malformations of SWS, historically called angiomata, result from somatic pathogenic variants in fetal ectodermal tissues that cause inappropriate control or maturation of capillary blood vessel formation [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The
         <em>
          GNAQ
         </em>
         gene encodes a guanine nucleotide binding protein, G protein subunit alpha q, that functions to regulate intracellular signaling pathways. The p.Arg183Gln somatic
         <em>
          GNAQ
         </em>
         pathogenic variant activates a set of signaling pathways that are thought to result in either nonsyndromic port wine stains or SWS, depending upon what stage of embryonic development is affected [
         <a href="#rid1">
          1
         </a>
         ]. Somatic pathogenic variants in
         <em>
          GNAQ
         </em>
         occurring at a later stage in embryogenesis may affect only precursors of vascular endothelial cells and lead to nonsyndromic port wine stains, while those occurring at an earlier stage may affect a greater variety of precursor cells and lead to SWS.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           GNA11
          </em>
         </strong>
         <strong>
          pathogenic variants
         </strong>
         – Atypical SWS associated with pathogenic variants in
         <em>
          GNA11
         </em>
         has been reported in a small number of patients [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <em>
          GNA11
         </em>
         also encodes a guanine nucleotide binding protein, G protein subunit alpha 11, which has an approximately 90 percent amino acid sequence identity with G protein subunit alpha q [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurologic injury
         </strong>
         – The reasons for neurologic involvement and progression in SWS are uncertain. A possible mechanism is hypoxic-ischemic injury to tissue adjacent to the leptomeningeal capillary-venous malformation. This is supported by findings in some patients of reduced cellular glucose metabolism, possibly resulting from decreased cerebral blood flow [
         <a href="#rid2">
          2,6-8
         </a>
         ]. Other proposed mechanisms are venous occlusion and increased venous pressure.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         SWS is characterized by a facial capillary malformation, also known as a port wine stain  (
         <a class="graphic graphic_picture graphicRef73343" href="/z/d/graphic/73343.html" rel="external">
          picture 1
         </a>
         ), and an associated leptomeningeal capillary-venous malformation (leptomeningeal angioma) involving the brain and eye [
         <a href="#rid9">
          9
         </a>
         ]. These vascular malformations are associated with specific neurologic and ocular abnormalities.
        </p>
        <p>
         The neurologic features of SWS may be progressive and include seizures, focal neurologic deficits, and intellectual disability. Visual field defects are common when the occipital cortex is affected. These manifestations occur with variable severity. Hydrocephalus also may occur [
         <a href="#rid10">
          10
         </a>
         ]. This complication is thought to result from increased venous pressure caused by thrombosis of the deep venous channels or extensive arteriovenous anastomoses. A small proportion of patients have no neurologic abnormalities. The neurologic manifestations of SWS associated with
         <em>
          GNA11
         </em>
         pathogenic variants may be milder than typical SWS caused by
         <em>
          GNAQ
         </em>
         pathogenic variants [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="local">
          'Genetics and pathogenesis'
         </a>
         above.)
        </p>
        <p>
         Ocular features of SWS include glaucoma and capillary-venous vascular malformations of the conjunctiva, episclera, choroid, and retina [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Port wine stain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous port wine stain (capillary malformation) is the most common type of vascular malformation, occurring in 0.3 percent of newborn infants  (
         <a class="graphic graphic_picture graphicRef73343" href="/z/d/graphic/73343.html" rel="external">
          picture 1
         </a>
         ). However, only a small proportion of children with port wine stains have SWS. (See
         <a class="medical medical_review" href="/z/d/html/13726.html" rel="external">
          "Capillary malformations (port wine birthmarks) and associated syndromes"
         </a>
         .)
        </p>
        <p>
         In SWS, the port wine stain typically is present on the forehead and upper eyelid, primarily in the distribution of the first or second division of the trigeminal nerve [
         <a href="#rid14">
          14
         </a>
         ]. In one report, 274 patients had port wine stains located in the distribution of the trigeminal nerve, and involvement of the eye or central nervous system was noted in 22 (8 percent) [
         <a href="#rid15">
          15
         </a>
         ]. All 22 patients of these patients had a port wine stain in the first or second division of the trigeminal nerve. Although overlapping the trigeminal distribution, the pattern of capillary malformations in SWS may actually reflect the embryonic vascular supply of the face [
         <a href="#rid16">
          16
         </a>
         ]. Although traditionally considered important in determining meningeal involvement risk, the location of the capillary malformation (port wine stain) on the face is not a good indicator of the risk of an underlying meningeal capillary malformation. Extension of the skin lesion to both sides of the face and the trunk and extremities is common.
        </p>
        <p>
         The skin lesion usually is obvious at birth. However, its appearance changes with age and its size increases as the patient grows. In the newborn, the lesion is flat and usually light pink in color. It typically darkens with age to a deep red, port wine appearance, and vascular ectasias may develop  (
         <a class="graphic graphic_picture graphicRef58831" href="/z/d/graphic/58831.html" rel="external">
          picture 2
         </a>
         ). The vascular ectasias produce nodularity and superficial blebbing, which lead to overgrowth of the underlying soft tissues and sometimes the bone. Dental abnormalities may occur as a result of gingival thickening if this area is affected. By the fifth decade, 65 percent of patients with a facial port wine stain have hypertrophy and nodularity within the lesion [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Leptomeningeal vascular malformation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A leptomeningeal capillary-venous malformation (LCVM), historically referred to as leptomeningeal angioma, occurs in 10 to 20 percent of cases when a typical facial lesion is present. The intracerebral capillary-venous malformation usually occurs on the same side as the port wine stain. The parietal and occipital areas are affected most commonly, although any portion of the cerebrum can be involved. LCVM seldom occurs without an accompanying facial capillary malformation [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         The pathologic appearance of the leptomeninges includes thickening and discoloration caused by the increased vascularity. The LCVM typically fills the subarachnoid space in the sulci, and large tortuous venous structures most commonly drain into the deep venous system, but they may also drain into superficial veins. The underlying parenchyma may be atrophic and contain multiple calcific granular deposits  (
         <a class="graphic graphic_diagnosticimage graphicRef138286" href="/z/d/graphic/138286.html" rel="external">
          image 1
         </a>
         ). The intraparenchymal calcification is the result of chronic tissue ischemia caused by venous stasis, a phenomenon known as dystrophic calcification.
        </p>
        <p>
         There is evidence that the LCVM in SWS are not static lesions but rather undergo angiogenic remodeling. In one study, the abnormal tissue vessels showed an increased expression of vascular endothelial growth factor (VEGF), VEGF receptors, and angiopoietin receptor TIE2 [
         <a href="#rid19">
          19
         </a>
         ]. These findings may lead to the development of new therapeutic strategies in SWS.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Seizures and epilepsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a series of 171 patients with SWS, seizures occurred in 80 percent [
         <a href="#rid20">
          20
         </a>
         ]. Several reports have found that bilateral port wine stains are associated with an increased risk of epilepsy [
         <a href="#rid20">
          20-22
         </a>
         ]. As an example, in the series of 171 subjects with SWS, seizures were more common with bilateral than unilateral port wine stains (87 versus 71 percent) [
         <a href="#rid20">
          20
         </a>
         ]. In another report, seizures occurred in 93 percent of patients with bilateral leptomeningeal lesions [
         <a href="#rid21">
          21
         </a>
         ]. In one case series of six patients with SWS who underwent epilepsy surgery, pathologic examination in all patients revealed a cortical malformation (polymicrogyria, cortical dysplasia) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Seizures in SWS may develop at any age, although they usually start in early childhood [
         <a href="#rid20">
          20,24,25
         </a>
         ]. In the study of 171 patients with SWS, seizures began by one, two, and five years of age in 75, 86, and 95 percent of affected patients, respectively [
         <a href="#rid20">
          20
         </a>
         ]. In another report of 77 children and adults with SWS and at least one witnessed seizure, the median age of seizure onset was six months [
         <a href="#rid24">
          24
         </a>
         ]. A pattern of severe seizures occurring in clusters was noted in 30 patients (39 percent). In patients with this pattern, seizures occurred in clusters of 1 to 21 (median 5) over a period of 1 to 10 days (median 2).
        </p>
        <p>
         Seizures are often the first symptom of SWS. They may occur in the setting of an acute illness and may be associated with the acute onset of hemiparesis. (See
         <a class="local">
          'Hemiparesis and stroke-like events'
         </a>
         below.)
        </p>
        <p>
         Initially, seizures are typically focal, but they often become generalized tonic-clonic. Less often, infantile spasms or myoclonic or atonic seizures are seen.
        </p>
        <p>
         The success of controlling seizures with antiseizure medication is variable and unpredictable. Some patients have long intervals without seizures, even without medication, while others have frequent or prolonged seizures despite high doses of multiple medications. (See
         <a class="local">
          'Epilepsy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Hemiparesis and stroke-like events
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hemiparesis often develops acutely in conjunction with the onset of seizures [
         <a href="#rid9">
          9
         </a>
         ]. The deficit occurs contralateral to the intracranial lesion. The paretic extremity usually does not grow at a normal rate, resulting in hemiatrophy.
        </p>
        <p>
         Some affected children have progressive loss of motor function or have a series of stroke-like events. The mechanism for this deterioration is uncertain. Possible mechanisms include a cumulative effect of repeated thrombotic events within the LCVM or chronic disturbance of blood flow and oxygen delivery to the involved tissues.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Intellectual disability
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with SWS typically develop normally for several months after birth, after which they manifest developmental delay. However, the course of cognitive change in children with SWS is highly variable, including both increases and decreases in intelligence quotient (IQ) over time. Factors associated with a lower IQ at follow-up in one longitudinal study included baseline abnormalities on electroencephalography (EEG), high seizure frequency, and early frontal lobe involvement on brain MRI [
         <a href="#rid26">
          26
         </a>
         ]. Cognitive impairment can be obvious soon after birth, especially in infants with extensive brain involvement.
        </p>
        <p>
         In one report, intellectual disability was present in 60 percent of patients and was severe in 33 percent [
         <a href="#rid27">
          27
         </a>
         ]. In another study, intellectual disability was present in approximately one-half of affected adults [
         <a href="#rid28">
          28
         </a>
         ].
        </p>
        <p>
         Cognitive function is poorest in patients with bilateral intracerebral lesions. In one report of 122 patients with SWS, only 8 percent of patients with bilateral LCVMs had average intelligence [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Behavioral problems
         </span>
         <span class="headingEndMark">
          —
         </span>
         Behavioral problems are more common in children with SWS than in their unaffected siblings [
         <a href="#rid29">
          29
         </a>
         ]. The risk for behavioral problems is associated with poorer cognitive function and the presence of epilepsy [
         <a href="#rid29">
          29,30
         </a>
         ]. However, behavioral problems can occur in patients with normal intelligence. Autism spectrum disorder and social communication difficulties are also associated with SWS [
         <a href="#rid31">
          31
         </a>
         ]. The results of one small retrospective study suggested that patients with SWS may be at increased risk of suicidal thoughts or behaviors compared with patients with other neurologic conditions [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Visual field defects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many patients have visual field defects, typically a homonymous hemianopia. This is due to the presence of a LCVM affecting one or both occipital lobes and optic tracts. (See
         <a class="medical medical_review" href="/z/d/html/5247.html" rel="external">
          "Homonymous hemianopia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H941379">
         <span class="h2">
          Glaucoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         The predominant ocular abnormality of SWS is glaucoma (increased intraocular pressure), which occurs in approximately one-half of affected patients. Therefore, we suggest ophthalmology referral and follow-up for all patients presenting with SWS and for all infants and children presenting with a capillary malformation involving the upper and lower eyelids and/or extensive lesions in the frontotemporal region (V1 and V2 segments).
        </p>
        <p>
         The risk of glaucoma is highest in the first decade. Congenital glaucoma is seen in approximately one-half of patients with SWS and presents in newborns with enlargement of the globe (buphthalmos). Occasional patients develop glaucoma as adults. Thus, continued vigilance is needed, even in patients with initially normal intraocular pressure. (See
         <a class="medical medical_review" href="/z/d/html/6272.html" rel="external">
          "Overview of glaucoma in infants and children", section on 'Sturge-Weber syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H941386">
         <span class="h2">
          Other ophthalmologic findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other ophthalmologic complications include vascular anomalies, heterochromia of the iris, and visual field defects [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Capillary-venous malformation of the choroid (also known as choroidal hemangioma) occurs in 30 to 40 percent of patients with SWS and can lead to increased intraocular pressure [
         <a href="#rid12">
          12,33,34
         </a>
         ]. These lesions may be diffuse or localized within the retina  (
         <a class="graphic graphic_picture graphicRef74289" href="/z/d/graphic/74289.html" rel="external">
          picture 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Episcleral and conjunctival lesions include anomalous vessels or capillary-venous malformations [
         <a href="#rid35">
          35
         </a>
         ]. In a series of 51 children with SWS, episcleral or conjunctival hemangiomas occurred in 69 percent [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heterochromia of the iris originally was noted by Weber. The more deeply pigmented iris usually is ipsilateral to the facial angioma. The pigmentation is caused by aggregated melanocytic hamartomata on the anterior surface of the iris.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H941075">
         <span class="h2">
          Neuroendocrine aspects
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of growth hormone deficiency in SWS is increased up to 18-fold compared with the general population [
         <a href="#rid36">
          36
         </a>
         ]. Growth hormone deficiency occurs without neuroimaging evidence of pituitary or hypothalamic abnormalities. Central hypothyroidism has also been reported in SWS [
         <a href="#rid37">
          37
         </a>
         ]. Since both of these conditions can be effectively treated, appropriate screening tests should be obtained if indicated.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of SWS is based upon demonstration of the facial capillary malformations and leptomeningeal capillary-venous malformations. Occasional patients who have the leptomeningeal lesion but no facial lesion are identified when neurologic problems develop. These patients also may have glaucoma or other ocular features of the disorder.
        </p>
        <p>
         SWS should be distinguished from Klippel-Trenaunay syndrome. In the latter, extensive capillary malformations associated with dysplastic veins involve the limbs and trunk, often with hypertrophy of the affected extremity.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          NEUROIMAGING
         </span>
         <span class="headingEndMark">
          —
         </span>
         The preferred neuroimaging technique for the diagnosis of SWS is brain MRI with gadolinium contrast, which demonstrates the presence of the leptomeningeal capillary-venous malformation and the extent of involvement with brain structures  (
         <a class="graphic graphic_diagnosticimage graphicRef138286" href="/z/d/graphic/138286.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef138284" href="/z/d/graphic/138284.html" rel="external">
          image 2
         </a>
         ) [
         <a href="#rid38">
          38,39
         </a>
         ]. There is a general consensus among experts that a negative brain MRI with gadolinium at one year of age can reliably exclude the presence of a leptomeningeal lesion. If MRI is not available, cranial computed tomography can identify brain calcification and provide some anatomic information  (
         <a class="graphic graphic_diagnosticimage graphicRef138286" href="/z/d/graphic/138286.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef138284" href="/z/d/graphic/138284.html" rel="external">
          image 2
         </a>
         ).
        </p>
        <p>
         Earlier imaging during infancy is generally not indicated. In some cases, leptomeningeal involvement may not be detected by neuroimaging during infancy and becomes apparent later [
         <a href="#rid2">
          2
         </a>
         ]. Thus, SWS cannot be ruled out by a normal brain MRI in the first few months of life. In addition, approximately 90 percent of infants with facial port wine stains do not have an intracranial lesion and would be expected to develop normally. Given these data, and the need to sedate infants for MRI, it is reasonable to perform imaging in infancy only if specific ocular and neurologic abnormalities (glaucoma, seizures, or hemiparesis) are present.
        </p>
        <p>
         Limited retrospective data suggest that neuroimaging with CT or MRI has a low yield for patients with SWS who develop acute neurologic symptoms. In a single-center study of 136 patients with SWS who presented to the emergency department (mainly with seizures, stroke-like episodes, and/or headaches), 73 had neuroimaging but none of the imaging studies revealed acute ischemic stroke or intracranial hemorrhage [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         No specific treatment exists for SWS. The cutaneous, ocular, and neurologic manifestations are treated with mixed success.
        </p>
        <p class="headingAnchor" id="H4241261704">
         <span class="h2">
          Epilepsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of seizures in SWS often is difficult. In one report, adequate control was accomplished with antiseizure medications in approximately 40 percent of cases [
         <a href="#rid41">
          41
         </a>
         ]. Antiseizure medications are standard first-line therapy for patients with epilepsy related to SWS [
         <a href="#rid24">
          24,42
         </a>
         ], though the optimal regimen is unknown. In a retrospective, single center report that analyzed a database of 108 subjects with SWS and one or more prior seizures,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         and
         <a class="drug drug_general" data-topicid="9467" href="/z/d/drug information/9467.html" rel="external">
          oxcarbazepine
         </a>
         were associated with better seizure control than
         <a class="drug drug_general" data-topicid="9904" href="/z/d/drug information/9904.html" rel="external">
          levetiracetam
         </a>
         , but no drug was clearly superior [
         <a href="#rid43">
          43
         </a>
         ]. The strength of these observations is limited by the small sample size and retrospective nature of the study.
        </p>
        <p>
         In refractory cases, hemispherectomy or more limited surgical resection of epileptogenic tissue may be beneficial, although data are limited [
         <a href="#rid25">
          25,44-47
         </a>
         ]. Most studies suggest that focal resections are less likely to result in good seizure control than hemispherectomy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a survey of 70 patients identified by the Sturge-Weber Foundation who had a hemispherectomy between 1979 and 2001, 81 percent of the 32 who responded were free of seizures and 53 percent were off anticonvulsants [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a retrospective review of 27 children with SWS who had surgery for medically resistant epilepsy, functional or anatomic hemispherectomy was followed by complete resolution of seizures in eight of eight patients; with focal resection, seizure-free outcome was reported of 11 of 19 (58 percent) [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Thus, some experts recommend surgery with hemispherectomy, lobectomy or transection of the corpus callosum for patients with SWS and medically resistant epilepsy (eg, poor seizure control despite treatment for six months with a minimum of two anticonvulsants), particularly when associated with clinically significant hemiparesis, visual field loss, and developmental delay [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3794613223">
         <span class="h2">
          Cutaneous lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Port wine stains can be treated by selective photothermolysis using a pulsed dye laser. This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/13638.html" rel="external">
          "Laser and light therapy for cutaneous vascular lesions", section on 'Capillary malformations (port wine birthmarks)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2043465812">
         <span class="h2">
          Glaucoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         The development of topical medications has improved the medical management of glaucoma in SWS [
         <a href="#rid13">
          13
         </a>
         ]. However, topical treatment often is ineffective in normalizing intraocular pressure [
         <a href="#rid49">
          49
         </a>
         ]. In these cases, the surgical treatment depends upon the etiology of the glaucoma. (See
         <a class="medical medical_review" href="/z/d/html/6272.html" rel="external">
          "Overview of glaucoma in infants and children", section on 'Sturge-Weber syndrome'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1437858084">
         <span class="h2">
          Low-dose aspirin
         </span>
         <span class="headingEndMark">
          —
         </span>
         For all children diagnosed with SWS, we suggest treatment with low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (3 to 5 mg/kg per day) beginning in infancy [
         <a href="#rid50">
          50
         </a>
         ]. There is increasing agreement among experienced clinicians that low dose aspirin may be beneficial, with the rationale that antithrombotic therapy may prevent the progression of impaired cerebral blood flow and hypoxic-ischemic neuronal injury [
         <a href="#rid8">
          8,51-53
         </a>
         ]. Limited observational data suggest that low-dose aspirin may reduce the frequency and severity of seizures and stroke-like events [
         <a href="#rid6">
          6,54,55
         </a>
         ]. However, no controlled studies exist. There is no increased risk of intracranial hemorrhage in patients with SWS whether on aspirin or not.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis for SWS depends upon the extent of brain and skin involvement, and the age of seizure onset. In a study of 277 participants (two months to 66 years of age) with SWS, the extent of the port-wine birthmark was associated with an increased risk of epilepsy and of glaucoma surgery, while the presence of bilateral leptomeningeal capillary-venous malformations (LCVMs) was associated with both learning disorder and intellectual disability [
         <a href="#rid56">
          56
         </a>
         ]. Similarly, a report of 112 patients with SWS found that the extent of LCVM was associated with seizure severity [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p>
         The occurrence of seizures, the age at seizure onset, and the response to treatment also affect prognosis. Earlier onset of seizures (eg, before one year) and poor response to anticonvulsant therapy are associated with a greater likelihood of cognitive and motor impairment [
         <a href="#rid20">
          20,56,58
         </a>
         ].
        </p>
        <p>
         Neurologic function may deteriorate with age. As a result, approximately one-half of affected adults are impaired, including those who initially were normal.
        </p>
        <p class="headingAnchor" id="H2670895538">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/122570.html" rel="external">
          "Society guideline links: Sturge-Weber syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H35507872">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sturge-Weber syndrome (SWS) is a rare congenital vascular disorder that affects capillary size blood vessels. SWS is caused by somatic mosaic pathogenic variants in the
         <em>
          GNAQ
         </em>
         gene. It is not a heritable disorder. (See
         <a class="local">
          'Genetics and pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         SWS is characterized by facial capillary malformation (port wine stain) and associated capillary-venous malformations affecting the brain and eye. These vascular malformations are associated with specific ocular and neurologic abnormalities. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cutaneous port wine stain is the most common type of vascular malformation, occurring in 0.3 percent of newborn infants  (
         <a class="graphic graphic_picture graphicRef73343" href="/z/d/graphic/73343.html" rel="external">
          picture 1
         </a>
         ). However, only a small proportion of children with port wine stains have SWS. The port wine stain of SWS typically is present on the forehead and upper eyelid, primarily in the distribution of the first or second division of the trigeminal nerve. Although traditionally considered important in determining meningeal involvement risk, the location of the port wine stain on the face is not a good indicator of the risk of an underlying meningeal capillary malformation. (See
         <a class="local">
          'Port wine stain'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A leptomeningeal capillary-venous malformation (LCVM; angioma) occurs in 10 to 20 percent of cases when a typical facial lesion is present. The intracerebral lesion usually occurs on the same side as the port wine stain. The parietal and occipital areas are affected most commonly. (See
         <a class="local">
          'Leptomeningeal vascular malformation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ocular features of SWS include glaucoma, vascular malformations of the conjunctiva, episclera, choroid  (
         <a class="graphic graphic_picture graphicRef74289" href="/z/d/graphic/74289.html" rel="external">
          picture 3
         </a>
         ) and retina, and heterochromia of the iris. (See
         <a class="local">
          'Glaucoma'
         </a>
         above and
         <a class="local">
          'Other ophthalmologic findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The neurologic features of SWS may be progressive and include seizures, focal neurologic deficits, visual field defects, and intellectual disability. These problems occur with variable severity. A small proportion of patients have no neurologic abnormalities. Seizures in SWS may develop at any age, although they usually start in early childhood. Hemiparesis often develops acutely in conjunction with the onset of seizures. Some affected children have progressive loss of motor function or have a series of stroke-like events. (See
         <a class="local">
          'Seizures and epilepsy'
         </a>
         above and
         <a class="local">
          'Hemiparesis and stroke-like events'
         </a>
         above and
         <a class="local">
          'Intellectual disability'
         </a>
         above and
         <a class="local">
          'Behavioral problems'
         </a>
         above and
         <a class="local">
          'Visual field defects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis of SWS is based upon demonstration of the facial and leptomeningeal vascular malformations. Occasional patients who have the LCVM but no facial lesion are identified when neurologic problems develop. SWS should be distinguished from Klippel-Trenaunay-Weber syndrome in which extensive capillary angiomata associated with dysplastic veins involve the limbs and trunk, often with hypertrophy of the affected extremity. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The preferred diagnostic neuroimaging technique for SWS is brain MRI with gadolinium contrast, which demonstrates the presence of the LCVM and the extent of involvement with brain structures  (
         <a class="graphic graphic_diagnosticimage graphicRef138286" href="/z/d/graphic/138286.html" rel="external">
          image 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef138284" href="/z/d/graphic/138284.html" rel="external">
          image 2
         </a>
         ). A negative brain MRI with gadolinium at one year of age can reliably exclude the presence of leptomeningeal lesion. (See
         <a class="local">
          'Neuroimaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No specific treatment exists for SWS. The cutaneous, ocular, and neurologic manifestations are managed with mixed success. Observational data suggest that low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         may be beneficial. Therefore, for all children diagnosed with SWS, we suggest treatment with low-dose aspirin (3 to 5 mg/kg per day) beginning in infancy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). There is no increased risk of intracranial hemorrhage in patients with SWS whether on aspirin or not. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3366083692">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges John B Bodensteiner, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Shirley MD, Tang H, Gallione CJ, et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med 2013; 368:1971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comi AM. Presentation, diagnosis, pathophysiology, and treatment of the neurological features of Sturge-Weber syndrome. Neurologist 2011; 17:179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Happle R. Lethal genes surviving by mosaicism: a possible explanation for sporadic birth defects involving the skin. J Am Acad Dermatol 1987; 16:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thorpe J, Frelin LP, McCann M, et al. Identification of a Mosaic Activating Mutation in GNA11 in Atypical Sturge-Weber Syndrome. J Invest Dermatol 2021; 141:685.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jansen P, Müller H, Lodde GC, et al. GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors. Front Genet 2021; 12:663272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maria BL, Neufeld JA, Rosainz LC, et al. Central nervous system structure and function in Sturge-Weber syndrome: evidence of neurologic and radiologic progression. J Child Neurol 1998; 13:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee JS, Asano E, Muzik O, et al. Sturge-Weber syndrome: correlation between clinical course and FDG PET findings. Neurology 2001; 57:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comi AM. Update on Sturge-Weber syndrome: diagnosis, treatment, quantitative measures, and controversies. Lymphat Res Biol 2007; 5:257.
          </a>
         </li>
         <li class="breakAll">
          Bodensteiner JB, Roach ES. Sturge-Weber syndrome: Introduction and overview. In: Sturge-Weber Syndrome, 2nd edition, Bodensteiner JB, Roach ES (Eds), Sturge-Weber Foundation, Mt. Freedom, NJ 2010.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishman MA, Baram TZ. Megalencephaly due to impaired cerebral venous return in a Sturge-Weber variant syndrome. J Child Neurol 1986; 1:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dompmartin A, van der Vleuten CJM, Dekeuleneer V, et al. GNA11-mutated Sturge-Weber syndrome has distinct neurological and dermatological features. Eur J Neurol 2022; 29:3061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sullivan TJ, Clarke MP, Morin JD. The ocular manifestations of the Sturge-Weber syndrome. J Pediatr Ophthalmol Strabismus 1992; 29:349.
          </a>
         </li>
         <li class="breakAll">
          Cheng KP. Ophthalmologic manifestations of Sturge-Weber syndrome. In: Sturge-Weber Syndrome, Bodensteiner JB, Roach ES (Eds), Sturge-Weber Foundation, Mt. Freedom, NJ 1999. p.17.
         </li>
         <li class="breakAll">
          Bodensteiner JB. Sturge-Weber Syndrome. In: Vascular Birthmarks of the Head and Neck, Hochman M (Ed), Facial Plastic Surgery Clinics of North America, 2001. p.569.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tallman B, Tan OT, Morelli JG, et al. Location of port-wine stains and the likelihood of ophthalmic and/or central nervous system complications. Pediatrics 1991; 87:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waelchli R, Aylett SE, Robinson K, et al. New vascular classification of port-wine stains: improving prediction of Sturge-Weber risk. Br J Dermatol 2014; 171:861.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geronemus RG, Ashinoff R. The medical necessity of evaluation and treatment of port-wine stains. J Dermatol Surg Oncol 1991; 17:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aydin A, Cakmakçi H, Kovanlikaya A, Dirik E. Sturge-Weber syndrome without facial nevus. Pediatr Neurol 2000; 22:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comati A, Beck H, Halliday W, et al. Upregulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha in leptomeningeal vascular malformations of Sturge-Weber syndrome. J Neuropathol Exp Neurol 2007; 66:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sujansky E, Conradi S. Sturge-Weber syndrome: age of onset of seizures and glaucoma and the prognosis for affected children. J Child Neurol 1995; 10:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bebin EM, Gomez MR. Prognosis in Sturge-Weber disease: comparison of unihemispheric and bihemispheric involvement. J Child Neurol 1988; 3:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaseka ML, Bitton JY, Décarie JC, Major P. Predictive Factors for Epilepsy in Pediatric Patients With Sturge-Weber Syndrome. Pediatr Neurol 2016; 64:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maton B, Krsek P, Jayakar P, et al. Medically intractable epilepsy in Sturge-Weber syndrome is associated with cortical malformation: implications for surgical therapy. Epilepsia 2010; 51:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kossoff EH, Ferenc L, Comi AM. An infantile-onset, severe, yet sporadic seizure pattern is common in Sturge-Weber syndrome. Epilepsia 2009; 50:2154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang S, Pan J, Zhao M, et al. Characteristics, surgical outcomes, and influential factors of epilepsy in Sturge-Weber syndrome. Brain 2022; 145:3431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bosnyák E, Behen ME, Guy WC, et al. Predictors of Cognitive Functions in Children With Sturge-Weber Syndrome: A Longitudinal Study. Pediatr Neurol 2016; 61:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pascual-Castroviejo I, Díaz-Gonzalez C, García-Melian RM, et al. Sturge-Weber syndrome: study of 40 patients. Pediatr Neurol 1993; 9:283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sujansky E, Conradi S. Outcome of Sturge-Weber syndrome in 52 adults. Am J Med Genet 1995; 57:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapieski L, Friedman A, Lachar D. Psychological functioning in children and adolescents with Sturge-Weber syndrome. J Child Neurol 2000; 15:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raches D, Hiscock M, Chapieski L. Behavioral and academic problems in children with Sturge-Weber syndrome: differences between children with and without seizures. Epilepsy Behav 2012; 25:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gittins S, Steel D, Brunklaus A, et al. Autism spectrum disorder, social communication difficulties, and developmental comorbidities in Sturge-Weber syndrome. Epilepsy Behav 2018; 88:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sebold AJ, Ahmed AS, Ryan TC, et al. Suicide Screening in Sturge-Weber Syndrome: An Important Issue in Need of Further Study. Pediatr Neurol 2020; 110:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baselga E. Sturge-Weber syndrome. Semin Cutan Med Surg 2004; 23:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Singh AD, Kaiser PK, Sears JE. Choroidal hemangioma. Ophthalmol Clin North Am 2005; 18:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phelps CD. The pathogenesis of glaucoma in Sturge-Weber syndrome. Ophthalmology 1978; 85:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller RS, Ball KL, Comi AM, Germain-Lee EL. Growth hormone deficiency in Sturge-Weber syndrome. Arch Dis Child 2006; 91:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comi AM, Bellamkonda S, Ferenc LM, et al. Central hypothyroidism and Sturge-Weber syndrome. Pediatr Neurol 2008; 39:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Truhan AP, Filipek PA. Magnetic resonance imaging. Its role in the neuroradiologic evaluation of neurofibromatosis, tuberous sclerosis, and Sturge-Weber syndrome. Arch Dermatol 1993; 129:219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabeti S, Ball KL, Bhattacharya SK, et al. Consensus Statement for the Management and Treatment of Sturge-Weber Syndrome: Neurology, Neuroimaging, and Ophthalmology Recommendations. Pediatr Neurol 2021; 121:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jülich K, Neuberger I, Sahin M, et al. Yield of Emergent Neuroimaging in Patients With Sturge-Weber Syndrome Presenting With Acute Neurologic Symptoms. J Child Neurol 2019; 34:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arzimanoglou A, Aicardi J. The epilepsy of Sturge-Weber syndrome: clinical features and treatment in 23 patients. Acta Neurol Scand Suppl 1992; 140:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comi A. Current Therapeutic Options in Sturge-Weber Syndrome. Semin Pediatr Neurol 2015; 22:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan EH, Kossoff EH, Bachur CD, et al. Anticonvulsant Efficacy in Sturge-Weber Syndrome. Pediatr Neurol 2016; 58:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arzimanoglou AA, Andermann F, Aicardi J, et al. Sturge-Weber syndrome: indications and results of surgery in 20 patients. Neurology 2000; 55:1472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vining EP, Freeman JM, Pillas DJ, et al. Why would you remove half a brain? The outcome of 58 children after hemispherectomy-the Johns Hopkins experience: 1968 to 1996. Pediatrics 1997; 100:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kossoff EH, Buck C, Freeman JM. Outcomes of 32 hemispherectomies for Sturge-Weber syndrome worldwide. Neurology 2002; 59:1735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bourgeois M, Crimmins DW, de Oliveira RS, et al. Surgical treatment of epilepsy in Sturge-Weber syndrome in children. J Neurosurg 2007; 106:20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Comi AM. Sturge-Weber syndrome and epilepsy: an argument for aggressive seizure management in these patients. Expert Rev Neurother 2007; 7:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Emelen C, Goethals M, Dralands L, Casteels I. Treatment of glaucoma in children with Sturge-Weber syndrome. J Pediatr Ophthalmol Strabismus 2000; 37:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeom S, Comi AM. Updates on Sturge-Weber Syndrome. Stroke 2022; 53:3769.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puttgen KB, Lin DD. Neurocutaneous vascular syndromes. Childs Nerv Syst 2010; 26:1407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bay MJ, Kossoff EH, Lehmann CU, et al. Survey of aspirin use in Sturge-Weber syndrome. J Child Neurol 2011; 26:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lance EI, Sreenivasan AK, Zabel TA, et al. Aspirin use in Sturge-Weber syndrome: side effects and clinical outcomes. J Child Neurol 2013; 28:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Day AM, Hammill AM, Juhász C, et al. Hypothesis: Presymptomatic treatment of Sturge-Weber Syndrome With Aspirin and Antiepileptic Drugs May Delay Seizure Onset. Pediatr Neurol 2019; 90:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Udani V, Pujar S, Munot P, et al. Natural history and magnetic resonance imaging follow-up in 9 Sturge-Weber Syndrome patients and clinical correlation. J Child Neurol 2007; 22:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Day AM, McCulloch CE, Hammill AM, et al. Physical and Family History Variables Associated With Neurological and Cognitive Development in Sturge-Weber Syndrome. Pediatr Neurol 2019; 96:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugano H, Iimura Y, Igarashi A, et al. Extent of Leptomeningeal Capillary Malformation is Associated With Severity of Epilepsy in Sturge-Weber Syndrome. Pediatr Neurol 2021; 117:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luat AF, Behen ME, Chugani HT, Juhász C. Cognitive and motor outcomes in children with unilateral Sturge-Weber syndrome: Effect of age at seizure onset and side of brain involvement. Epilepsy Behav 2018; 80:202.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6159 Version 31.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23656586" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21712663" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Presentation, diagnosis, pathophysiology, and treatment of the neurological features of Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3033033" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Lethal genes surviving by mosaicism: a possible explanation for sporadic birth defects involving the skin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32771470" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Identification of a Mosaic Activating Mutation in GNA11 in Atypical Sturge-Weber Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34040639" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9881531" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Central nervous system structure and function in Sturge-Weber syndrome: evidence of neurologic and radiologic progression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11468301" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Sturge-Weber syndrome: correlation between clinical course and FDG PET findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18370916" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Update on Sturge-Weber syndrome: diagnosis, treatment, quantitative measures, and controversies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18370916" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Update on Sturge-Weber syndrome: diagnosis, treatment, quantitative measures, and controversies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3598114" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Megalencephaly due to impaired cerebral venous return in a Sturge-Weber variant syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35715928" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : GNA11-mutated Sturge-Weber syndrome has distinct neurological and dermatological features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1287171" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The ocular manifestations of the Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1287171" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The ocular manifestations of the Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1287171" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The ocular manifestations of the Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1805804" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Location of port-wine stains and the likelihood of ophthalmic and/or central nervous system complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24976116" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : New vascular classification of port-wine stains: improving prediction of Sturge-Weber risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1991884" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The medical necessity of evaluation and treatment of port-wine stains.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10913734" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Sturge-Weber syndrome without facial nevus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17204940" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Upregulation of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha in leptomeningeal vascular malformations of Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7769179" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Sturge-Weber syndrome: age of onset of seizures and glaucoma and the prognosis for affected children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3209844" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Prognosis in Sturge-Weber disease: comparison of unihemispheric and bihemispheric involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27637568" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Predictive Factors for Epilepsy in Pediatric Patients With Sturge-Weber Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19780796" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Medically intractable epilepsy in Sturge-Weber syndrome is associated with cortical malformation: implications for surgical therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19389148" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : An infantile-onset, severe, yet sporadic seizure pattern is common in Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34932802" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Characteristics, surgical outcomes, and influential factors of epilepsy in Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27353695" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Predictors of Cognitive Functions in Children With Sturge-Weber Syndrome: A Longitudinal Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8216540" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Sturge-Weber syndrome: study of 40 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7645596" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Outcome of Sturge-Weber syndrome in 52 adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11063079" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Psychological functioning in children and adolescents with Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23000106" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Behavioral and academic problems in children with Sturge-Weber syndrome: differences between children with and without seizures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30195931" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Autism spectrum disorder, social communication difficulties, and developmental comorbidities in Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32660870" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Suicide Screening in Sturge-Weber Syndrome: An Important Issue in Need of Further Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15295918" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15763200" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Choroidal hemangioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/662281" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The pathogenesis of glaucoma in Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16551788" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Growth hormone deficiency in Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18555176" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Central hypothyroidism and Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8434982" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Magnetic resonance imaging. Its role in the neuroradiologic evaluation of neurofibromatosis, tuberous sclerosis, and Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34153815" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Consensus Statement for the Management and Treatment of Sturge-Weber Syndrome: Neurology, Neuroimaging, and Ophthalmology Recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30378435" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Yield of Emergent Neuroimaging in Patients With Sturge-Weber Syndrome Presenting With Acute Neurologic Symptoms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1279926" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The epilepsy of Sturge-Weber syndrome: clinical features and treatment in 23 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26706016" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Current Therapeutic Options in Sturge-Weber Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26997037" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Anticonvulsant Efficacy in Sturge-Weber Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11094100" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Sturge-Weber syndrome: indications and results of surgery in 20 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9240794" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Why would you remove half a brain? The outcome of 58 children after hemispherectomy-the Johns Hopkins experience: 1968 to 1996.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12473761" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Outcomes of 32 hemispherectomies for Sturge-Weber syndrome worldwide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17233308" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Surgical treatment of epilepsy in Sturge-Weber syndrome in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17678489" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Sturge-Weber syndrome and epilepsy: an argument for aggressive seizure management in these patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10714693" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Treatment of glaucoma in children with Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36263782" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Updates on Sturge-Weber Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20582592" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Neurocutaneous vascular syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21427442" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Survey of aspirin use in Sturge-Weber syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23112247" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Aspirin use in Sturge-Weber syndrome: side effects and clinical outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30482419" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Hypothesis: Presymptomatic treatment of Sturge-Weber Syndrome With Aspirin and Antiepileptic Drugs May Delay Seizure Onset.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17621534" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Natural history and magnetic resonance imaging follow-up in 9 Sturge-Weber Syndrome patients and clinical correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30853154" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Physical and Family History Variables Associated With Neurological and Cognitive Development in Sturge-Weber Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33677229" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Extent of Leptomeningeal Capillary Malformation is Associated With Severity of Epilepsy in Sturge-Weber Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29414553" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Cognitive and motor outcomes in children with unilateral Sturge-Weber syndrome: Effect of age at seizure onset and side of brain involvement.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
